Using Eravacycline to treat multidrug-resistant pneumonia
The Effectiveness and Safety Study of Eravacycline Combination Therapy for Multidrug-Resistant Acinetobacter Baumannii Pneumonia
This study is testing if a new combination of antibiotics, including eravacycline, can help people with pneumonia caused by hard-to-treat bacteria feel better and clear the infection.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fujian Medical University Union Hospital Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06282835 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness and safety of eravacycline combination therapy in patients with pneumonia caused by multidrug-resistant Acinetobacter baumannii. Participants will receive eravacycline along with polymyxin or other suitable antibiotics, and their blood and epithelial lining fluid drug concentrations will be monitored. The study will assess clinical efficacy and microbiological clearance rates over a treatment period of at least four days.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with pneumonia caused by drug-sensitive strains of Acinetobacter baumannii.
Not a fit: Patients who are pregnant, have concurrent severe infections, or are in a moribund state may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new effective treatment option for patients suffering from multidrug-resistant pneumonia.
How similar studies have performed: While this approach is novel in the context of eravacycline for this specific infection, similar combination therapies have shown promise in treating multidrug-resistant infections.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ≥18 years old; 2. Meets the diagnostic criteria for pneumonia specified by the Chinese Medical Association Respiratory Branch. 3. CRAB is identified or predominant pathogenic bacteria, and drug sensitivity test indicates that Eravacycline is sensitive to the strain; 4. Patients expected to receive Eravacycline for ≥4 days; 5. Has already signed the informed consent Exclusion Criteria: 1. Pregnant or lactating; 2. Concurrent intracranial infection, urinary tract infection, or bloodstream infection; 3. Individuals in a moribund state; 4. The investigator believes there is any medical history, current condition, treatment, laboratory abnormalities, or other circumstances that may affect the trial results, interrupt the trial process (or the subject's inability to complete all trial requirements, operations, and visits), or increase the subject's risk with the experimental medication. Patients with terminal illnesses or evidence of immediately life-threatening diseases are excluded; 5. Patients with a history of allergic reactions to tetracyclines or any excipients in the investigational drug formulation
Where this trial is running
Fuzhou, Fujian
- Fujian Medical University Union hospital — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Principal investigator: Hui Zhang, PhD — Fujian Medical University Union Hospital
- Study coordinator: Hui Zhang, PhD
- Email: xhzh@fjmu.edu.cn
- Phone: +86 130 1572 3860
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.